Sepiapterin Reductase (SPR)

Sepiapterin Reductase (SPR)

Overview

Sepiapterin Reductase (SPR) is the final enzyme in the de novo biosynthesis of tetrahydrobiopterin (BH4), the essential cofactor for aromatic amino acid hydroxylases and nitric oxide synthases [@blau2003]. SPR catalyzes the two-step NADPH-dependent reduction of 6-pyruvoyl tetrahydropterin (PTPS product) through intermediate 7,8-dihydropterin to BH4. SPR deficiency (SRD) is a rare autosomal recessive neurometabolic disorder that presents with dopa-responsive dystonia, and common variants in the SPR gene have been associated with altered Parkinson's disease risk. SPR also plays a role in the regulation of monoamine neurotransmitter synthesis, making it relevant to understanding dopaminergic and serotonergic pathways in neurodegeneration.

Sepiapterin Reductase (SPR)

Overview

Sepiapterin Reductase (SPR) is the final enzyme in the de novo biosynthesis of tetrahydrobiopterin (BH4), the essential cofactor for aromatic amino acid hydroxylases and nitric oxide synthases [@blau2003]. SPR catalyzes the two-step NADPH-dependent reduction of 6-pyruvoyl tetrahydropterin (PTPS product) through intermediate 7,8-dihydropterin to BH4. SPR deficiency (SRD) is a rare autosomal recessive neurometabolic disorder that presents with dopa-responsive dystonia, and common variants in the SPR gene have been associated with altered Parkinson's disease risk. SPR also plays a role in the regulation of monoamine neurotransmitter synthesis, making it relevant to understanding dopaminergic and serotonergic pathways in neurodegeneration.

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2">Sepiapterin Reductase Protein</th></tr>
<tr><td>Protein Name</td><td>Sepiapterin Reductase (SPR)</td></tr>
<tr><td>Gene</td><td>SPR</td></tr>
<tr><td>UniProt ID</td><td>[P35270](https://www.uniprot.org/uniprot/P35270)</td></tr>
<tr><td>PDB IDs</td><td>1QPD, 2NBQ, 1ZTR</td></tr>
<tr><td>Molecular Weight</td><td>27.8 kDa</td></tr>
<tr><td>Subcellular Localization</td><td>Cytosol</td></tr>
<tr><td>Protein Family</td><td>Short-chain dehydrogenase/reductase (SDR) family</td></tr>
<tr><td>EC Number</td><td>1.5.1.34</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">216 edges</a></td>
</tr>
</table>
</div>

Structure

SPR is a 261-amino acid enzyme belonging to the short-chain dehydrogenase/reductase (SDR) superfamily [@tachida2020]:

Enzyme Architecture

Catalytic Mechanism

SPR catalyzes two sequential NADPH-dependent reductions:

The two reductions use one NADPH per step, consuming a total of 2 NADPH per BH4 molecule synthesized. The reaction proceeds via a ping-pong bi-bi mechanism.

Structural Studies

• 1QPD: Saccharomyces cerevisiae SPR complexed with NADPH (2.0 Å resolution) — reveals cofactor binding mode
• 1ZTR: Human SPR in complex with cofactor and inhibitor analogs (1.8 Å) — guides drug design
• 2NBQ: Mutant SPR variants from SRD patients — structure-function relationships
• AlphaFold2: Predicted full-length human SPR structure consistent with biochemical data

Normal Function

Tetrahydrobiopterin Biosynthesis

SPR catalyzes the final step in the BH4 de novo synthesis pathway [@clarke2019]:

GTP → GCH1 (GTP cyclohydrolase I) → 7,8-dihydroneopterin triphosphate
→ PTS (6-pyruvoyltetrahydropterin synthase) → 6-pyruvoyl tetrahydropterin
→ PCBD1 (pterin-4-alpha-carbinolamine dehydratase) → 6,7,8-trihydropterin
→ SPR → BH4 (tetrahydrobiopterin)

SPR is the rate-limiting step only under certain metabolic conditions, as the pathway can be regulated at the GCH1 step.

Cofactor Functions of BH4

BH4 serves as an essential cofactor for:

Biological Significance

• Neurotransmitter synthesis: BH4 is the obligate cofactor for all monoamine neurotransmitter synthesis (dopamine, norepinephrine, epinephrine, serotonin)
• Vascular tone: BH4-dependent NO production regulates cerebral blood flow and neurovascular coupling
• Antioxidant defense: BH4 is a potent antioxidant that scavenges reactive oxygen species
• Neural development: BH4 is required for proper brain development and synaptic plasticity

Role in Disease

Sepiapterin Reductase Deficiency (SRD)

SRD (OMIM #612716) is a rare autosomal recessive neurometabolic disorder caused by biallelic mutations in SPR [@thny2002; @friedman2011]:

Clinical presentation:

• Dopa-responsive dystonia (DRD): Childhood-onset dystonia that markedly improves with L-DOPA treatment. Dystonia may be focal, segmental, or generalized.
• Diurnal fluctuation: Symptoms characteristically worsen throughout the day ("fatigue dystonia") and improve with rest
• Parkinsonism: Bradykinesia, rigidity, and tremor in some patients
• Developmental delay: Variable cognitive involvement
• Hypotonia: Often present in infancy
• Spasticity: Some patients develop upper motor neuron signs
• Ptosis and oculogyric crises: Eye movement abnormalities

• Elevated sepiapterin in CSF (pathognomonic) — sepiapterin accumulates because the reduction step is blocked
• Decreased BH4 in CSF
• Normal/neither phenylalanine in plasma (distinguishes from BH4 synthesis disorders upstream of sepiapterin)
• Normal pterin pattern in urine (no elevated neopterin)

• Autosomal recessive inheritance
• Common mutations: p.R150C, p.G161R, p.L72P, splice site mutations
• Genotype-phenotype correlation is imperfect — residual enzyme activity determines severity

L-DOPA is highly effective in SRD — dramatic and sustained response is a diagnostic hallmark [@zurf2022].

Parkinson's Disease

SPR variants influence PD risk through BH4-dependent pathways [@nsengimana2022]:

• GWAS signals: Common variants near SPR have been associated with altered PD risk in some cohorts
• BH4 and dopamine: Reduced BH4 → reduced TH activity → impaired dopamine synthesis
• Oxidative stress: BH4 is a potent antioxidant — reduced BH4 may increase vulnerability to oxidative damage in dopaminergic neurons
• GCH1 connection: Both GCH1 and SPR affect the BH4 pathway; GCH1 variants are strong PD risk factors
• Therapeutic relevance: BH4 supplementation and L-DOPA are being explored as neuroprotective strategies in PD

Alzheimer's Disease and Other Neurodegeneration

• BH4 in AD: BH4 levels are reduced in AD brain; BH4 supplementation is neuroprotective in animal models
• NO signaling: BH4-dependent NOS regulation affects cerebral blood flow and neurovascular coupling
• Vascular contributions: Impaired BH4-NO pathway may contribute to vascular dementia and mixed dementia

Protein Interactions

| Partner | Interaction Type | Functional Consequence |
|---------|----------------|----------------------|
| GCH1 | Sequential pathway | Upstream enzyme providing substrate |
| PTS | Sequential pathway | Produces PTPS, upstream of SPR |
| PCBD1 | Sequential pathway | Produces 6,7,8-trihydropterin substrate |
| PTPS | Sequential pathway | Alternative pathway for BH4 salvage |
| NADPH | Cofactor binding | Provides reducing equivalents |
| TH (tyrosine hydroxylase) | Downstream enzyme | BH4 cofactor for dopamine synthesis |
| TPH2 (tryptophan hydroxylase) | Downstream enzyme | BH4 cofactor for serotonin synthesis |
| NOS1 (nNOS) | Downstream enzyme | BH4 cofactor for NO synthesis |

Research Directions

See Also

• [SPR Gene](/genes/spr)
• [Tetrahydrobiopterin Pathway](/mechanisms/bh4-biosynthesis)
• [Dopa-Responsive Dystonia](/diseases/dopa-responsive-dystonia)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Dopamine Biosynthesis](/mechanisms/dopamine-biosynthesis)
• [GCH1 Protein](/proteins/gch1-protein)
• [BH4 Deficiency](/mechanisms/bh4-deficiency)
• [Neurotransmitter Biosynthesis](/mechanisms/neurotransmitter-biosynthesis)

References

Protein Interaction Network

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Aquaporin-4 Polarization Rescue](/hypothesis/h-c8ccbee8) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: AQP4
• [Microglial Purinergic Reprogramming](/hypothesis/h-5daecb6e) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: P2RY12
• [Context-Dependent CRISPR Activation in Specific Neuronal Subtypes](/hypothesis/h-63b7bacd) — <span style="color:#81c784;font-weight:600">0.62</span> · Target: Cell-type-specific essential genes
• [Sphingolipid Metabolism Reprogramming](/hypothesis/h-6657f7cd) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: CERS2
• [Complement C1q Subtype Switching](/hypothesis/h-5a55aabc) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: C1QA
• [Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Targeting](/hypothesis/h-3a4f2027) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: HTT, DMPK, repeat-containing transcripts
• [Glial Glycocalyx Remodeling Therapy](/hypothesis/h-c35493aa) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: HSPG2
• [Ephrin-B2/EphB4 Axis Manipulation](/hypothesis/h-e6437136) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: EPHB4

Related Analyses:

• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [CRISPR-based therapeutic approaches for neurodegenerative diseases](/analysis/SDA-2026-04-02-gap-crispr-neurodegeneration-20260402) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving Sepiapterin Reductase (SPR) discovered through SciDEX knowledge graph analysis: